USRE39300E1 - Inhibiting the development of tolerance to and/or dependence on an addictive substance - Google Patents
Inhibiting the development of tolerance to and/or dependence on an addictive substance Download PDFInfo
- Publication number
- USRE39300E1 USRE39300E1 US09/880,881 US88088101A USRE39300E US RE39300 E1 USRE39300 E1 US RE39300E1 US 88088101 A US88088101 A US 88088101A US RE39300 E USRE39300 E US RE39300E
- Authority
- US
- United States
- Prior art keywords
- opium
- addictive substance
- morphine
- substance
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
Definitions
- This invention relates to a composition containing an addictive substance and a component which inhibits the development of tolerance to and/or dependence on the addictive substance. More particularly, the invention relates to a composition containing an addictive substance such as morphine or codeine and at least one nontoxic substance that blocks the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that blocks at least one major intracellular consequence of NMDA receptor activation, e.g., a ganglioside such as ganglioside GM 1 or GT 1b , a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide.
- NMDA N-methyl-D-aspartate
- Morphine is a rapid and effective drug for the treatment of severe pain but its long term administration has been limited due to its negative side effects, principally tolerance and dependence, which develop rapidly after administration. In an effort to make morphine of greater use in the treatment of pain, it has been combined with a variety of substances intended to inhibit one or more of its undesirable side effects.
- U.S. Pat. No. 2,770,569 describes the combination of morphine with the compound levo-d-hydroxy-N-allyl-morphinan which is said to suppress or eliminate such undesirable side reactions of morphine as depression, nausea and vomiting.
- 4,126,684 discloses reducing either the addiction liability of an addictive substance such as a narcotic analgesic or a barbiturate or the withdrawal symptoms caused by deprivation of such a substance in an addicted subject by administering the addictive substance, e.g., morphine, with a 4-amino-3-p-halophenylbutyric acid.
- U.S. Pat. No. 4,415,871 describes the prevention of treatment tolerance and physical dependence in chronic morphine treatment by combining the morphine with any of the specific dipeptides indicated therein.
- U.S. Pat. No. 5,041,446 discloses inhibiting the development of tolerance to morphine by combining the morphine with dapiprazole.
- 5,057,519 achieves a reduction in morphine tolerance by combining the morphine with a benzamide antagonist for a subtype of the serotonin receptor, 5-HT 3.
- a benzamide antagonist for a subtype of the serotonin receptor, 5-HT 3. Trujillo et al., “Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801”, Science, 251 (4989), pp. 85-87, Jan. 4, 1991; Tanganelli et al., “Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs”, Neuroscience Letters, 122(2), pp. 270-272, Jan.
- Marek et al. “Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat”, Brain Research, 547(1), pp. 77-81, Apr. 26, 1991; and, Marek et al., “Delayed application of MK-801 attenuates development of morphine tolerance in rats, Brain Research, 558(1), pp. 163-165, Aug. 30, 1991 discuss the role of MK-801 (the compound 5-methyl-10,11-dihydro-SH-dibenzo[a,d]cyclohepten-5,10-imine), an NMDA receptor antagonist or blocker, in reducing morphine dependence in laboratory animals.
- MK-801 has been found to be toxic and is therefore unsuitable for pharmaceutical use.
- composition which comprises an addictive substance and at least one nontoxic substance that blocks the N-methyl-D-aspartate receptor or at least one major intracellular consequence of N-methyl-D-aspartate receptor activation.
- a method of inhibiting the development of tolerance to and/or dependence on an addictive substance administered to a mammal which is liable to addiction thereto comprises administering the addictive substance to the mammal before, with or following administration to the mammal of a tolerance-reducing and/or dependence-reducing amount of at least one non-toxic substance that blocks the N-methyl-D-aspartate receptor or at least one major intracellular consequence of N-methyl-D-aspartate receptor activation.
- a method of alleviating withdrawal symptoms in a mammal addicted to an addictive substance comprises administering to the addicted mammal the addictive substance before, with or following administration to the mammal of a dependence-reducing amount of at least one nontoxic substance that blocks the N-methyl-D-aspartate receptor or the intracellular consequences of N-methyl-D-aspartate receptor activation thereby alleviating withdrawal symptoms when the addictive substance is withdrawn from the mammal.
- nontoxic as used herein shall be understood in a relative sense and is intended to designate any substance that has been approved by the United States Food and Drug Administration (“FDA”) for administration to humans or, in keeping with established criteria, is susceptible to approval by the FDA for administration to humans.
- FDA United States Food and Drug Administration
- FIGS. 1-10 are graphical representations of experimental data demonstrating the effectiveness of specific nontoxic substances that block the N-methyl-D-aspartate receptor or a major consequence of N-methyl-D-aspartate receptor activation for inhibiting morphone tolerance and dependence in rats.
- narcotic analgesics e.g., opiates, opiate derivatives, opioids and their pharmaceutically acceptable salts.
- narcotic analgesics include alfentanyl, alphaprodine, anileridine, bezitramide, codeine, dihydrocodeine, diphenoxylate, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, isomethadone, levomethorphan, levorphanol, metazocine, methadone, metopon, morphine, opium extracts, opium fluid extracts, powdered opium, granulated opium, raw opium, tincture of opium, oxycodone, oxymorphone, pethidine, phenazocine, piminodine, racemethorphan, racemorphan, thebainc and pharmaceutically acceptable salts thereof.
- acetorphine acetyldihydrocodeine, acetylmethadol, allylprodine, alphracetylmethadol, alphameprodine, alphamethadol, benzethidine, benzylmorphine, betacetylmethadol, betameprodine, betamethadol, betaprodine, clonitazene, cocaine, codeine, methylbromide, codeine-N-oxide, cyprenorphine, desomorphine, dextromoramide, diampromide, diethylthiambutene, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiamubutene, dioxaphetyl butyrate, dipipanone, drotebanol, ethanol, ethylmethylthiambutene, eton itazene, e
- Still other addictive substances that can be utilized in the practice of the invention include the sedatives and hypnotics, e.g., benzodiazepines such as chlordiazepoxide, chlorazepate, diazepam, flurazepam, halazepam, ketazolam, borazepam, oxazepam, prazepam, temazepam, triazolam and the pharmaceutically acceptable salts thereof, barbiturates such as amobarbital, ambobarbital, barbital, butabartital, mephobarbital, methohexital, pentobarbital, phenobarbital, secobarbital, talbutal, thiamylal and thiopental and the pharmaceutically acceptable salts thereof and other sedatives and hypnotics such as chloral hydrate, meprobamate, methaqualone, methyprylon and the pharmaceutically acceptable salts thereof.
- the addictive substance is administered before, with or following the administration of at least one nontoxic substance that blocks the N-methyl-D-aspartate (NMDA) receptor or the intracellular consequences of N-methyl-D-aspartate receptor activation.
- NMDA N-methyl-D-aspartate
- Activation of the NMDA receptor induces a number of changes in the functional activity of nerve cells, and in particular, their capacity for excitability or inhibition in the presence of an addictive substance, via an increase in intracellular Ca++ concentration.
- the major consequences of NMDA receptor activation include the following sequences, or cascades, of events occurring within nerve cells:
- a substance that blocks the NMDA receptor will effectively prevent all of the foregoing major intracellular sequences of events from taking place. However, even with activation of the NMDA receptor, it is still possible to inhibit the development of tolerance to and/or dependence on an addictive substance by combining the addictive substance with a substance that blocks at least one of the foregoing major intracellular sequences of events.
- a substance that interferes with translocation and activation of protein kinase C or with calmodulin induced activation of constitutive nitric oxide synthase as well as induction of inducible nitric oxide synthase is also useful for the practice of this invention.
- nontoxic substances that block the NMDA receptor and as such are useful in the practice of the present invention are morphinans such as dextromethorphan ((+)-3-hydroxy-N-methylmorphinan) and dextrorphan ((+)-3-hydroxy-N-methylmorphinan), their mixtures and the pharmaceutically acceptable salts thereof.
- morphinans such as dextromethorphan ((+)-3-hydroxy-N-methylmorphinan) and dextrorphan ((+)-3-hydroxy-N-methylmorphinan), their mixtures and the pharmaceutically acceptable salts thereof.
- Other useful nontoxic substances that block the NMDA receptor include ketamine (2-(2-chlorophenyl)-2-(methylamino)cyclohexanone), pyrroloquinoline quinone and cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid.
- Nontoxic substances that block a major intracellular consequence of NMDA receptor activation and are therefore useful in the practice of the invention include inhibitors of protein kinase C such as the gangliosides, in particular, ganglioside GM 1 (monosialoganglioside) and ganglioside GT 1b (trisialoganglioside); amphipathic long chain bases such as sphingosine, N,N,N-trimethylsphingosine, sphinganine and psychosine; quinolyloxazole-2 -ones such as 4-methyl-5-(3-quinolinyl)- 2-(3H)-oxazolone and phenyl-5-(2-quinolinyl)-2-3(3H)-oxazolone; 1,4-bis-(amino-hydroxyalkylamino)anthraquinones such as 1,4-bis-(3-propylamino-2-hydroxypropylamino)-9,10 anthracenedione
- Additional nontoxic substances that block a major intracellular consequence of NMDA receptor activation and as such are useful in the practice of the invention include inhibitors of calmodulin such as the phenothiazines, in particular, chlorpromazine, chlorpromazine sulfoxide, prochlorperazine dimaleate, perphenazine, trifluoperazine, fluphenazine, fluphenazine enanthate, fluphenazine decanoate, thioridazine, mesoridazine besylate, piperacetazine, acetophenazine dimaleate, carphenazine dimaleate, butaperazine dimaleate and phenothiazine sulfoxide; naphthalenesulfonamides such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, N-(6-aminohexyl)-5-chloro-2-na
- composition of this invention can be in the form of a single dosage unit containing both the addictive substance and the nontoxic substance that blocks the NMDA receptor or a major intracellular consequence of NMDA receptor activation or the two substances can be administered separately provided both are ultimately present in effective amounts in the patient.
- Introduction of the composition into the patient can be by way of oral administration or by intravenous, intramuscular, subcutanous, intrathecal, epidural or intracerebroventricular injection.
- the preferred dosage of addictive substance and the nontoxic substance that blocks the NMDA receptor or a major intracellular consequence of NMDA receptor activation can vary widely, e.g., from about 0.25 to about 250 mg/day, but actual amounts will vary according to the particular active substances being used, the particular formulation containing the active substances and tile state and circumstances of the host being treated. As those skilled in the art recognize, many factors that modify the action of the active substances herein will be taken into account by the treating physician such as the age, body weight, sex, diet and condition of the subject, the time of administration, the rate and route of administration, and so forth. Optimal dosages for a given set of conditions can be ascertained by those skilled in the art using conventional dosage determination tests in view of the experimental data provided herein.
- the substance that blocks the NMDA receptor or a major intracellular consequence of NMDA receptor activation can be administered to the subject, together with the addictive substance, at a dosage rate of about 0.25 to about 250 mg/day, again, specific dosage levels and routes of administration being selected in accordance with the subject's circumstances.
- the subject will experience a reduced level of dependence on the addictive substance eventually reaching the point where total withdrawal of the substance will result in at most mild withdrawal symptoms.
- composition herein can be formulated as a liquid, powder, elixir, injectable solution, etc.
- Formulations for oral use can be provided as hard gelatin capsules wherein the composition is mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the composition is mixed with an oleaginous medium, e.g., liquid paraffin or olive oil.
- Aqueous suspensions can contain the composition in admixture with pharmaceutically acceptable excipients such as suspensing agents, e.g., sodium carboxymethyl cellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrol idone, gum tragacanth and gum acacia, dispersing or wetting agents such as naturally occurring phosphatide, e.g., lecithin, or condensation products of an alkylene oxide with fatty acids, e.g., polyoxyethylene stearate, or condensation products of ethylene oxide with long chain al iphatic alcohols, e.g., heptadecaethyleneoxycetanol, or condensation products of ethylene exide with partial esters derived from fatty acids and a hexitol, e.g., polyoxyethylene sorbitol monoleate or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, e.g., poly
- Such aqueous suspensions can also contain one or more preservatives, e.g., ethyl- or n-propyl-p-hydroxy benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, saccharin or sodium or calcium cyclamate.
- preservatives e.g., ethyl- or n-propyl-p-hydroxy benzoate
- coloring agents e.g., ethyl- or n-propyl-p-hydroxy benzoate
- flavoring agents e.g., ethyl- or n-propyl-p-hydroxy benzoate
- sweetening agents such as sucrose, saccharin or sodium or calcium cyclamate.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the composition in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above.
- Additional excipients e.g., sweetening, flavoring and coloring agents, can also be present.
- Syrups and elixirs can be formulated with sweetening agents, for example glycerol, sorbitol or sucrose. Such formulations can also contain a demulcent, a preservative and flavoring and coloring agents.
- composition of this invention or either of its principal active ingredients can be provided in sustained release dosage form of which many kinds are known, e.g., as described in U.S. Pat. Nos. 4,788,055; 4,816,264; 4,828,836; 4,834,965; 4,834,985; 4,996,047; 5,071,646; and, 5,133,974, the contents of which are incorporated by reference herein.
- FIG. 1 shows the effects of systemic doses of dextrorphan (DEX) on tolerance to morphine analgesia produced by twice daily subcutaneous administration of 10 mg/kg morphine.
- DEX dextrorphan
- Baseline scores were between 4 and 5 seconds (at Day 0) and post-drug scores measured 1 hour after drug administration were close to 10 seconds for the first 5 days of daily drug administration.
- the control group (open triangles) show marked reduction in response to morphine (i.e., tolerance) at 7 and 9 days.
- dextrorphan potently prevented the development of morphine tolerance as shown by no significant decreases in tail flick latencies, i.e., remaining analgesic during the whole course of repeated morphine administration. Asterisks indicate mean scores that were significantly different from those of the control group. All tested doses of dextrorphan were effective in preventing development of morphine tolerance with optimal doses ranging from 3.13 mg/kg to 12.5 mg/kg.
- FIG. 2 shows the effects of systemic doses of dextrorphan on jumping, a withdrawal symptom produced by subcutaneous naloxone (2 mg/kg) in rats previously injected with morphine (10 mg/kg) twice daily for 9 days.
- Asterisks indicate median number of jumps in dextrorphan treatment groups (MOR+DEX) that were significantly less than that of the control group (MOR+SAL).
- Vertical bars refer to the range of the numbers of jumps.
- 3.13 and 6.25 mg/kg dextrorphan (but not 1.56 mg/kg) significantly reduced the incidence of jumping in morphine tolerant rats, a behavioral manifestation of morphine dependence, brought about following subcutaneous injection with 2 mg/kg naloxone.
- coadministration of dextrorphan with morphine greatly inhibits the development of both tolerance to and dependence on morphine while the analgesic effect of the morphine remains substantially unaffected.
- ganglioside GM 1 in inhibiting morphine tolerance and dependence utilizing both systemic and intrathecal treatment was evaluated.
- all 3 doses of ganglioside GM 1 were effective, 30 and 60 mg/kg were more effective at days 9 and 10 than 10 mg/kg.
- FIG. 4 shows the effects of systemic doses of ganglioside GM 1 on jumping, a withdrawal symptom produced by subcutaneous naloxone (2 mg/kg) in rats previously injected with morphine (10 mg/kg) twice daily for 9 days.
- Asterisks indicate median number of jumps in GM 1 treatment groups (M+G) that were significantly less than that of the control group (MOR+SAL).
- Vertical bars refer to the range of the numbers of jumps. All three doses [10 mg/kg (10); 30 mg/kg (30); 60 mg/kg (60)] of GM 1 were effective with 60 mg/kg GM 1 being the most effective dose tested.
- This example demonstrates the effectiveness of ganglioside GM 1 in preventing the development of morphine tolerance at the site of the spinal cord.
- Morphine sulfate 10 ⁇ g was delivered once daily through an intrathecal (spinal) canula implanted 5 days before the first morphine injection.
- Ganglioside GM 1 or saline also was delivered intrathecally 30 minutes before each morphine injection.
- FIG. 5 shows the effects of the intrathecal doses of ganglioside GM 1 on tolerance to morphine analgesia produced by once daily intrathecal administration of 10 ⁇ g morphine.
- Intrathecal ganglioside GM 1 was given 30 min before each morphine administration.
- TL actual tail-flick latency
- BL baseline latency obtained before the first morphine injection
- 10 cut-off time for radiant heat stimulation.
- the control group open circle
- morphine i.e., tolerance
- Asterisks indicate mean scores that were significantly different from those of other groups.
- ganglioside GM 1 The effects of ganglioside GM 1 and the toxic NMDA receptor antagonist MK 801 on morphine tolerance were evaluated.
- Calmodulin is an intracellular colactor necessary for the nitric oxide pathway that can be initiated upon NMDA receptor activation.
- FIGS. 7-10 demonstrate that trifluoperazine (TFP) and N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride (W-7), both of which are calmodulin antagonists, effectively prevent the development of morphine tolerance in rats following intrathecal administration.
- rats receiving once daily morphine sulfate (10 ⁇ g) and saline injection given intrathecally for 7 consecutive days developed tolerance to the analgesic effect or morphine as indicated by the reliable decrease in tail-flick latencies as compared to baseline latencies (day 1).
- mice treated with TFP or W-7 (100 or 50 nmol) given immediately before each morphine administration showed a reliable analgesic effect of morphine (day 8) employing the same dose regimen used in the saline treatment group.
Abstract
Nontoxic substances that block the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that block a major intracellular consequence of NMDA-receptor activation, e.g., a ganglioside such as GM1 or GT1b, a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, inhibit the development of tolerance to and/or dependence on addictive drugs, e.g., narcotic analgesics such as morphine, codeine, etc.
Description
This is a continuation of application Ser. No. 08/043,280 filed Apr. 6, 1993, now U.S. Pat. No. 5,321,012, which is a continuation-in-part of U.S. patent application Ser. No. 08/010,583, filed Jan. 28, 1993, abandoned.
This invention relates to a composition containing an addictive substance and a component which inhibits the development of tolerance to and/or dependence on the addictive substance. More particularly, the invention relates to a composition containing an addictive substance such as morphine or codeine and at least one nontoxic substance that blocks the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that blocks at least one major intracellular consequence of NMDA receptor activation, e.g., a ganglioside such as ganglioside GM1 or GT1b, a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide.
Morphine is a rapid and effective drug for the treatment of severe pain but its long term administration has been limited due to its negative side effects, principally tolerance and dependence, which develop rapidly after administration. In an effort to make morphine of greater use in the treatment of pain, it has been combined with a variety of substances intended to inhibit one or more of its undesirable side effects. U.S. Pat. No. 2,770,569 describes the combination of morphine with the compound levo-d-hydroxy-N-allyl-morphinan which is said to suppress or eliminate such undesirable side reactions of morphine as depression, nausea and vomiting. U.S. Pat. No. 4,126,684 discloses reducing either the addiction liability of an addictive substance such as a narcotic analgesic or a barbiturate or the withdrawal symptoms caused by deprivation of such a substance in an addicted subject by administering the addictive substance, e.g., morphine, with a 4-amino-3-p-halophenylbutyric acid. U.S. Pat. No. 4,415,871 describes the prevention of treatment tolerance and physical dependence in chronic morphine treatment by combining the morphine with any of the specific dipeptides indicated therein. U.S. Pat. No. 5,041,446 discloses inhibiting the development of tolerance to morphine by combining the morphine with dapiprazole. U.S. Pat. No. 5,057,519 achieves a reduction in morphine tolerance by combining the morphine with a benzamide antagonist for a subtype of the serotonin receptor, 5-HT3. Trujillo et al., “Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801”, Science, 251 (4989), pp. 85-87, Jan. 4, 1991; Tanganelli et al., “Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs”, Neuroscience Letters, 122(2), pp. 270-272, Jan. 28, 1991; Marek et al., “Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat”, Brain Research, 547(1), pp. 77-81, Apr. 26, 1991; and, Marek et al., “Delayed application of MK-801 attenuates development of morphine tolerance in rats, Brain Research, 558(1), pp. 163-165, Aug. 30, 1991 discuss the role of MK-801 (the compound 5-methyl-10,11-dihydro-SH-dibenzo[a,d]cyclohepten-5,10-imine), an NMDA receptor antagonist or blocker, in reducing morphine dependence in laboratory animals. However, MK-801 has been found to be toxic and is therefore unsuitable for pharmaceutical use.
In accordance with the present invention, a composition is provided which comprises an addictive substance and at least one nontoxic substance that blocks the N-methyl-D-aspartate receptor or at least one major intracellular consequence of N-methyl-D-aspartate receptor activation.
Further in accordance with the present invention, a method of inhibiting the development of tolerance to and/or dependence on an addictive substance administered to a mammal which is liable to addiction thereto is provided which comprises administering the addictive substance to the mammal before, with or following administration to the mammal of a tolerance-reducing and/or dependence-reducing amount of at least one non-toxic substance that blocks the N-methyl-D-aspartate receptor or at least one major intracellular consequence of N-methyl-D-aspartate receptor activation.
Still further in accordance with this invention, a method of alleviating withdrawal symptoms in a mammal addicted to an addictive substance is provided which comprises administering to the addicted mammal the addictive substance before, with or following administration to the mammal of a dependence-reducing amount of at least one nontoxic substance that blocks the N-methyl-D-aspartate receptor or the intracellular consequences of N-methyl-D-aspartate receptor activation thereby alleviating withdrawal symptoms when the addictive substance is withdrawn from the mammal.
The term “nontoxic” as used herein shall be understood in a relative sense and is intended to designate any substance that has been approved by the United States Food and Drug Administration (“FDA”) for administration to humans or, in keeping with established criteria, is susceptible to approval by the FDA for administration to humans.
A particularly important category of addictive substances with which the present invention is concerned are the narcotic analgesics, e.g., opiates, opiate derivatives, opioids and their pharmaceutically acceptable salts. Specific examples of narcotic analgesics include alfentanyl, alphaprodine, anileridine, bezitramide, codeine, dihydrocodeine, diphenoxylate, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, isomethadone, levomethorphan, levorphanol, metazocine, methadone, metopon, morphine, opium extracts, opium fluid extracts, powdered opium, granulated opium, raw opium, tincture of opium, oxycodone, oxymorphone, pethidine, phenazocine, piminodine, racemethorphan, racemorphan, thebainc and pharmaceutically acceptable salts thereof. For a detailed discussion of these and other narcotic analgesics, reference may be made to Jaffe et al., “Opioid Analgesics and Antagonists” in “Goodman and Gillman's Pharmacological Basis of Therapeutics”, Goodman et al., eds. 7th ed., 1985, MacMillan and Company, New York pp. 491-531.
Other addictive substances that can be utilized herein include acetorphine, acetyldihydrocodeine, acetylmethadol, allylprodine, alphracetylmethadol, alphameprodine, alphamethadol, benzethidine, benzylmorphine, betacetylmethadol, betameprodine, betamethadol, betaprodine, clonitazene, cocaine, codeine, methylbromide, codeine-N-oxide, cyprenorphine, desomorphine, dextromoramide, diampromide, diethylthiambutene, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiamubutene, dioxaphetyl butyrate, dipipanone, drotebanol, ethanol, ethylmethylthiambutene, eton itazene, etorphine, etoxeridine, furethidine, hydromorphinol, hydroxypethidine, ketobemidone, levomoramide, levophenacylmorphan, methyldesorphine, methyldihydromorphine, morpheridine, morphine methylpromide, morphine methylsulfonate, morphine-N-oxide, myrophine, nicocodeine, nicomorphine, nicotine, noracymethadol, norlevorphanol, normethadone, normorphine, norpipanone, phenadoxone, phenampromide, phenomorphtan, phenoperidine, piritramide, pholcodine, proheptazoine, properidine, propiran, racemoramide, thebacon, trimeperidine and the pharmaceutically acceptable salts thereof.
Still other addictive substances that can be utilized in the practice of the invention include the sedatives and hypnotics, e.g., benzodiazepines such as chlordiazepoxide, chlorazepate, diazepam, flurazepam, halazepam, ketazolam, borazepam, oxazepam, prazepam, temazepam, triazolam and the pharmaceutically acceptable salts thereof, barbiturates such as amobarbital, ambobarbital, barbital, butabartital, mephobarbital, methohexital, pentobarbital, phenobarbital, secobarbital, talbutal, thiamylal and thiopental and the pharmaceutically acceptable salts thereof and other sedatives and hypnotics such as chloral hydrate, meprobamate, methaqualone, methyprylon and the pharmaceutically acceptable salts thereof.
By way of inhibiting the development of tolerance to and/or dependence on any of the foregoing and similarly addictive substances, the addictive substance is administered before, with or following the administration of at least one nontoxic substance that blocks the N-methyl-D-aspartate (NMDA) receptor or the intracellular consequences of N-methyl-D-aspartate receptor activation. Activation of the NMDA receptor, a subtype of excitatory amino acid receptors, induces a number of changes in the functional activity of nerve cells, and in particular, their capacity for excitability or inhibition in the presence of an addictive substance, via an increase in intracellular Ca++ concentration. The major consequences of NMDA receptor activation include the following sequences, or cascades, of events occurring within nerve cells:
-
- a) translocation and activation of protein kinases such as protein kinase C→phosphorylation of substrate proteins such as cytosolic enzymes, channel proteins, receptor proteins, etc.→changes in functional activity;
- b) initiation of early gene (c-fos, c-jun, zif-268, etc.) expression by either increased intracellular Ca++ or Ca++-activated protein kinases→expression of functional genes responsible for production of cellular enzymes (such as protein kinases), receptor proteins (such as the NMDA receptor), ion channel proteins (such as K+, Na+, Ca++ channels), neuropeptides (such as dynorphin), etc.→changes in functional activity;
- c) Ca++/calmodulin (or other Ca++ binding proteins) induced activation of enzymes and other cellular components→activation of Ca++/calmodulin-protein kinase systems such as Ca++/calmodulin kinase II→autophosphorylation of enzymes (e.g., Ca++/calmodulin kinase II) or other functional proteins→changes in functional activity;
- d) Ca++/calmodulin induced activation of constitutive nitric oxide synthase as well as induction of inducible nitric oxide synthase→production of nitric oxide→i) production of cyclic guanosine monophosphate via activation of guanosine cyclase resulting in activation of protein kinases and early gene expression; ii) direct protein modification such as enzymes, receptor and/or channel proteins; iii) lipid membrane modification and/or nucleic acid modification via scavenge of free radicals; iv) induction of neurotoxicity at higher nitric oxide levels; v) retrograde actions in adjacent neurons or glial cells such as facilitation of glutamate release/NMDA receptor activation and/or inhibition of post-synaptic NMDA receptors→changes in functional activity;
- e) interactions with the cyclic adenosine monophosphate/protein kinase A system, the phospholipase C-inositol triphosphate-Ca++-/diacylglycerol-protein kinase system, the phospholipase A2-arachidonic acid/prostanoids/leukotrienes system→changes in functional activity induced by second messenger systems other than NMDA receptor/Ca++/Ca++-calmodulin/protein kinase systems; and,
- f) interactions with other excitatory amino acid receptor subtypes including non-NMDA receptors and metabotropic receptors as well as intracellular events subsequent to the activation of these excitatory amino acid receptor subtypes→changes in functional activity induced by the non-NMDA and metabotropic receptor activation.
A substance that blocks the NMDA receptor will effectively prevent all of the foregoing major intracellular sequences of events from taking place. However, even with activation of the NMDA receptor, it is still possible to inhibit the development of tolerance to and/or dependence on an addictive substance by combining the addictive substance with a substance that blocks at least one of the foregoing major intracellular sequences of events. Thus, e.g., a substance that interferes with translocation and activation of protein kinase C or with calmodulin induced activation of constitutive nitric oxide synthase as well as induction of inducible nitric oxide synthase is also useful for the practice of this invention.
Among the nontoxic substances that block the NMDA receptor and as such are useful in the practice of the present invention are morphinans such as dextromethorphan ((+)-3-hydroxy-N-methylmorphinan) and dextrorphan ((+)-3-hydroxy-N-methylmorphinan), their mixtures and the pharmaceutically acceptable salts thereof. Other useful nontoxic substances that block the NMDA receptor include ketamine (2-(2-chlorophenyl)-2-(methylamino)cyclohexanone), pyrroloquinoline quinone and cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid.
Nontoxic substances that block a major intracellular consequence of NMDA receptor activation and are therefore useful in the practice of the invention include inhibitors of protein kinase C such as the gangliosides, in particular, ganglioside GM1 (monosialoganglioside) and ganglioside GT1b (trisialoganglioside); amphipathic long chain bases such as sphingosine, N,N,N-trimethylsphingosine, sphinganine and psychosine; quinolyloxazole-2 -ones such as 4-methyl-5-(3-quinolinyl)- 2-(3H)-oxazolone and phenyl-5-(2-quinolinyl)-2-3(3H)-oxazolone; 1,4-bis-(amino-hydroxyalkylamino)anthraquinones such as 1,4-bis-(3-propylamino-2-hydroxypropylamino)-9,10 anthracenedione and 1,4 -bis-(3-benzylamino-2-hydroxypropylamino)-9,10 anthracenedione; and, mixtures and pharmaceutically acceptable salts of any of the foregoing.
Additional nontoxic substances that block a major intracellular consequence of NMDA receptor activation and as such are useful in the practice of the invention include inhibitors of calmodulin such as the phenothiazines, in particular, chlorpromazine, chlorpromazine sulfoxide, prochlorperazine dimaleate, perphenazine, trifluoperazine, fluphenazine, fluphenazine enanthate, fluphenazine decanoate, thioridazine, mesoridazine besylate, piperacetazine, acetophenazine dimaleate, carphenazine dimaleate, butaperazine dimaleate and phenothiazine sulfoxide; naphthalenesulfonamides such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, N-(6-aminohexyl)-5-chloro-2-naphthalenesulfonamide and N-(6-aminohexyl)-5-bromo-2-naphthalenesul fonamide; 4 -substituted-4H,6H-pyrrolo[1, 2-a][4,1] benzoxazepines such as 1,3-dihydro-1-((1-[(4-methyl-4H,6H-pyrrolo[1,2-a][4,1] benzoxazepin-4-yl)methyl]-4-piperidinyl}-2H-benzimidazol-2-one; benzhydryls such as N-[2] (diphenylmethylthioehtyl]-2-(trifluoromethyl)benzeneethanamine, N-[2 -(bis(4 -fluorophenyl)methylthio)ethyl]-2-(trifluoromethyl)benzenethanamine and N-[2-(bis(4-fluorophenyl)methylthio)ethyl]-3-(trifluoromethyl)benzeneethanamine; tricyclic antidepressant drugs such as imipramine, 2 -chloroimipramine and amitriptyline; penfluridol; haloperidol; pimozide; clozapine; calmidazolin; and, mixtures and pharmaceutically acceptable salts of any of the foregoing.
Administration of the composition of this invention can be in the form of a single dosage unit containing both the addictive substance and the nontoxic substance that blocks the NMDA receptor or a major intracellular consequence of NMDA receptor activation or the two substances can be administered separately provided both are ultimately present in effective amounts in the patient. Introduction of the composition into the patient can be by way of oral administration or by intravenous, intramuscular, subcutanous, intrathecal, epidural or intracerebroventricular injection.
The preferred dosage of addictive substance and the nontoxic substance that blocks the NMDA receptor or a major intracellular consequence of NMDA receptor activation can vary widely, e.g., from about 0.25 to about 250 mg/day, but actual amounts will vary according to the particular active substances being used, the particular formulation containing the active substances and tile state and circumstances of the host being treated. As those skilled in the art recognize, many factors that modify the action of the active substances herein will be taken into account by the treating physician such as the age, body weight, sex, diet and condition of the subject, the time of administration, the rate and route of administration, and so forth. Optimal dosages for a given set of conditions can be ascertained by those skilled in the art using conventional dosage determination tests in view of the experimental data provided herein.
In alleviating withdrawal symptoms in addicted subjects deprived of the addictive substance, the substance that blocks the NMDA receptor or a major intracellular consequence of NMDA receptor activation can be administered to the subject, together with the addictive substance, at a dosage rate of about 0.25 to about 250 mg/day, again, specific dosage levels and routes of administration being selected in accordance with the subject's circumstances. As a result of this treatment, the subject will experience a reduced level of dependence on the addictive substance eventually reaching the point where total withdrawal of the substance will result in at most mild withdrawal symptoms.
The composition herein can be formulated as a liquid, powder, elixir, injectable solution, etc. Formulations for oral use can be provided as hard gelatin capsules wherein the composition is mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the composition is mixed with an oleaginous medium, e.g., liquid paraffin or olive oil.
Aqueous suspensions can contain the composition in admixture with pharmaceutically acceptable excipients such as suspensing agents, e.g., sodium carboxymethyl cellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrol idone, gum tragacanth and gum acacia, dispersing or wetting agents such as naturally occurring phosphatide, e.g., lecithin, or condensation products of an alkylene oxide with fatty acids, e.g., polyoxyethylene stearate, or condensation products of ethylene oxide with long chain al iphatic alcohols, e.g., heptadecaethyleneoxycetanol, or condensation products of ethylene exide with partial esters derived from fatty acids and a hexitol, e.g., polyoxyethylene sorbitol monoleate or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, e.g., polyoxyethylene sorbitan monooleate. Such aqueous suspensions can also contain one or more preservatives, e.g., ethyl- or n-propyl-p-hydroxy benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, saccharin or sodium or calcium cyclamate.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the composition in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, e.g., sweetening, flavoring and coloring agents, can also be present. Syrups and elixirs can be formulated with sweetening agents, for example glycerol, sorbitol or sucrose. Such formulations can also contain a demulcent, a preservative and flavoring and coloring agents.
The composition of this invention or either of its principal active ingredients can be provided in sustained release dosage form of which many kinds are known, e.g., as described in U.S. Pat. Nos. 4,788,055; 4,816,264; 4,828,836; 4,834,965; 4,834,985; 4,996,047; 5,071,646; and, 5,133,974, the contents of which are incorporated by reference herein.
The examples that follow are illustrative of the invention.
The effect of systemic dextrorphan on prevention of the development of morphine tolerance and dependence was examined in Sprague-Dawley rats weighing 350-400 gm. Morphine tolerance was developed in the rats by twice daily subcutaneous injection of 10 mg/kg morphine sulfate. The analgesic effect of the morphine was examined by using the well known tail-flick test which measures the latency of tail-flick upon radiant heat stimulation. The latency of tail-flick test is defined as the time elapsed from the onset of radiant heat to the flick of the rat's tail. In order to examine the effect of dextrorphan on the development of morphine tolerance, each morphine-treated rat also received intraperitoneal administration of either dextrorphan (1.56, 3.13, 6.25, 12.5 mg/kg, n=5/group) or saline (n=6) given 30 minutes prior to each morphine administration.
The effects of ganglioside GM1 in inhibiting morphine tolerance and dependence utilizing both systemic and intrathecal treatment were evaluated. The systemic treatment procedure, including both morphine and ganglioside GM1 administration, was exactly the same as that used in the experimental work presented in Example 1 except that ganglioside GM1 was given 1 hour before each morphine administration.
As shown in FIG. 3 , the tail flick latency in ganglioside GM1-treated (10, 30, 60 mg/kg, n=6/group) rats remained significantly longer than that of saline-treated rats on days 5, 7, 9, and 10 of repeated morphine administration, indicating the prevention of the development of morphine tolerance by ganglioside GM1. Although all 3 doses of ganglioside GM1 were effective, 30 and 60 mg/kg were more effective at days 9 and 10 than 10 mg/kg.
This example demonstrates the effectiveness of ganglioside GM1 in preventing the development of morphine tolerance at the site of the spinal cord. Morphine sulfate 10 μg was delivered once daily through an intrathecal (spinal) canula implanted 5 days before the first morphine injection. Ganglioside GM1 or saline also was delivered intrathecally 30 minutes before each morphine injection.
The effects of ganglioside GM1 and the toxic NMDA receptor antagonist MK 801 on morphine tolerance were evaluated.
As shown in FIG. 6 , treatment with ganglioside GM1 (60 mg/kg) inhibited the development of morphine tolerance to the degree equivalent to that induced by 0.3 mg/kg MK 801. However, 50% (3 out of 6) of the rats treated with 0.3 mg/kg MK 801 died before the completion of the experiment and the remaining rats in the group showed apparently poor grooming and weight loss indicating adverse effects of MK 801 on health. The rats treated with ganglioside GM1 or dextrorphan continued to appear well groomed and did not show weight loss. None of the rats in the GM1 or dextrorphan treatment groups died due to drug administration. Thus, dextrorphan and GM1 are nontoxic in contrast to MK 801 which exhibits severe cytotoxic effects and as such, is unlikely to be approved by the FDA for administration to humans.
These examples illustrate the effects of the phenothiazine trifluoperazine (Example 5) and the naphthalenesulfonamide N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride (Example 6) in preventing the development of morphine tolerance in rats.
Calmodulin is an intracellular colactor necessary for the nitric oxide pathway that can be initiated upon NMDA receptor activation. FIGS. 7-10 demonstrate that trifluoperazine (TFP) and N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride (W-7), both of which are calmodulin antagonists, effectively prevent the development of morphine tolerance in rats following intrathecal administration. In both cases, rats receiving once daily morphine sulfate (10 μg) and saline injection given intrathecally for 7 consecutive days developed tolerance to the analgesic effect or morphine as indicated by the reliable decrease in tail-flick latencies as compared to baseline latencies (day 1). In contrast, rats treated with TFP or W-7 (100 or 50 nmol) given immediately before each morphine administration showed a reliable analgesic effect of morphine (day 8) employing the same dose regimen used in the saline treatment group. The prevention of the development of morphine tolerance by TFP or W-7 is dose-related: 100=50 nmol>25=12.5 nmol. Each data point in FIGS. 7-10 represents the mean of a group of rats (n=6) and standard errors are shown by vertical lines. The asterisks refer to statistical differences (α=0.05) between the saline group and each other group.
Claims (17)
1. A composition comprising an addictive substance and at least one nontoxic substance that blocks the N-methyl-D-aspartate receptor or a major intracellular consequence of N-methyl-D-aspartate receptor activation, the addictive substance being selected from the group consisting of alfentanyl, alphaprodine, anileridine, bezitramide, codeine, dihydrocodeine, diphenoxylate, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, isomethadone, levomethorphan, levorphanol, metazocine, methadone, metopon, morphine, opium extracts, opium fluid extracts, powdered opium, granulated opium, raw opium, tincture of opium, oxycodone, oxymorphone, pethidine, phenazocine, piminodine, racemethorphan, racemorphan and pharmaceutically acceptable salts thereof.
2. The composition of claim 1 in sustained release dosage form.
3. A formulated pharmaceutical composition comprising an addictive substance and at least one nontoxic synthetic substance that provides an improved effect for the addictive substance if used alone and that blocks the N-methyl-D-aspartate receptor and consists essentially of a morphinan or blocks a major intracellular consequence of N-methyl-D-aspartate receptor activation, the addictive substance being selected from the group consisting of alfentanyl, alphaprodine, anileridine, bezitramide, codeine, dihydrocodeine, diphenoxylate, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, isomethadone, levomethorphan, levorphanol, metazocine, methadone, metopon, morphine, opium extracts, opium fluid extracts, powdered opium, granulated opium, raw opium, tincture of opium, oxycodone, oxymorphone, pethidine, phenazocine, piminodine, racemethorphan, racemorphan and pharmaceutically acceptable salts thereof.
4. A formulated pharmaceutical composition comprising an addictive substance and a non-toxic synthetic substance, the addictive substance being selected from the group consisting of alfentanyl, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, isomethadone, levorphanol, methadone, morphine, oxycodone, oxymorphone, pethidine, and pharmaceutically acceptable salts thereof, the non-toxic synthetic substance providing an improved effect for the addictive substance if used alone and being selected from the group consisting of dextromethorphan, dextrorphan, and pharmaceutically acceptable salts thereof.
5. A formulated pharmaceutical composition comprising an addictive substance and a non-toxic synthetic substance, the addictive substance being selected from the group consisting of alfentanyl, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, isomethadone, levorphanol, morphine, oxycodone, oxymorphone, pethidine, and pharmaceutically acceptable salts thereof, the non-toxic synthetic substance being a blocker of the N-methyl-D-aspartate receptor and consisting essentially of morphinans, and providing an improved effect for the addictive substance if used alone.
6. A composition according to claims 3, 4 or 5 wherein the addictive substance is selected from the group consisting of alfentanyl, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, isomethadone, methadone, morphine, oxycodone, oxymorphone, pethidine, and pharmaceutically acceptable salts thereof.
7. A composition according to claims 3, 4 or 5 wherein the addictive substance is selected from the group consisting of alfentanyl, codeine, dihydrocodeine, fentanyl, isomethadone, methadone, pethidine, and pharmaceutically acceptable salts thereof.
8. A composition according to claims 3, 4 or 5 wherein the addictive substance is selected from the group consisting of codeine, methadone, and pharmaceutically acceptable salts thereof.
9. A composition according to claims 3, 4 or 5 wherein the addictive substance includes morphine or a pharmaceutically acceptable salt thereof.
10. A composition according to claims 3, 4 or 5 wherein the addictive substance includes oxycodone or a pharmaceutically acceptable salt thereof.
11. A composition according to claims 3, 4 or 5 wherein the addictive substance includes hydrocodone or a pharmaceutically acceptable salt thereof.
12. A composition according to claims 3, 4 or 5 wherein the addictive substance includes oxymorphone or a pharmaceutically acceptable salt thereof.
13. A composition according to claim 3 , 4 or 5 wherein the addictive substance includes hydromorphone or a pharmaceutically acceptable salt thereof.
14. A composition according to claims 3, 4 or 5, in oral dosage form.
15. A composition according to claims 3, 4 or 5, in sustained release dosage form.
16. A composition according to claims, 3, 4 or 5, in oral dosage and sustained release dosage form.
17. A formulated pharmaceutical composition comprising an addictive substance and at least one nontoxic synthetic substance that blocks the N-methyl-D-aspartate receptor or a major intracellular consequence of N-methyl-D-aspartate receptor activation, selected from pyrroloquinoline quinone and cis- 4 -(phosphonomethyl)- 2 -piperidinecarboxylic acid, the addictive substance being selected from the group consisting of alfentanyl, alphaprodine, anileridine, bezitramide, codeine, dihydrocodeine, diphenoxylate, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, isomethadone, levomethorphan, levorphanol, metazocine, methadone, metopon, morphine, opium extracts, opium fluid extracts, powdered opium, granulated opium, raw opium, tincture of opium, oxycodone, oxymorphone, pethidine, phenazocine, piminodine, racemethorphan, racemorphan, racemorphan and pharmaceutically acceptable salts thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/880,881 USRE39300E1 (en) | 1993-01-28 | 2001-06-15 | Inhibiting the development of tolerance to and/or dependence on an addictive substance |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1058393A | 1993-01-28 | 1993-01-28 | |
US08/043,280 US5321012A (en) | 1993-01-28 | 1993-04-06 | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
US08/245,970 US5556838A (en) | 1993-01-28 | 1994-05-19 | Inhibiting the development of tolerance to and/or dependence on an addictive substance |
US09/880,881 USRE39300E1 (en) | 1993-01-28 | 2001-06-15 | Inhibiting the development of tolerance to and/or dependence on an addictive substance |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/245,970 Reissue US5556838A (en) | 1993-01-28 | 1994-05-19 | Inhibiting the development of tolerance to and/or dependence on an addictive substance |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE39300E1 true USRE39300E1 (en) | 2006-09-19 |
Family
ID=27359265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/880,881 Expired - Lifetime USRE39300E1 (en) | 1993-01-28 | 2001-06-15 | Inhibiting the development of tolerance to and/or dependence on an addictive substance |
Country Status (1)
Country | Link |
---|---|
US (1) | USRE39300E1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060111308A1 (en) * | 2004-11-16 | 2006-05-25 | Wendye Robbins | Methods and compositions for therapeutic treatment |
US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
US20080241121A1 (en) * | 2007-04-02 | 2008-10-02 | Daniela Salvemini | Inhibitors of the ceramide metabolic pathway as adjuncts to opiates for pain |
US20100086543A1 (en) * | 2007-04-02 | 2010-04-08 | Saint Louis University | Compositions and methods for treating conditions associated with ceramide biosynthesis |
Citations (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2770569A (en) | 1952-08-01 | 1956-11-13 | Hoffmann La Roche | Analgesic compositions |
US4126684A (en) | 1976-02-11 | 1978-11-21 | Ciba-Geigy Corporation | 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse |
US4316888A (en) | 1980-04-15 | 1982-02-23 | Nelson Research & Development Co. | Method and composition of reducing pain |
US4362870A (en) | 1980-01-16 | 1982-12-07 | Regents Of The University Of Minnesota | Selective opioid receptor alkylating agents |
US4416871A (en) | 1978-07-10 | 1983-11-22 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition by peptides of tolerance to and physical dependence on morphine |
US4446140A (en) | 1981-12-10 | 1984-05-01 | Nelson Research & Development Company | Method and composition for treating mouth pain |
US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
US4476141A (en) | 1982-07-14 | 1984-10-09 | University Of Georgia Research Foundation, Inc. | Use of N-(6 aminohexyl)-5-chloro-1-naphthalenesulfonamide, N-(6 aminohexyl)-5-chloro-2-naphthalenesulfonamide, and N-(6 aminohexyl)-5-bromo-2-naphthalenesulfonamide as vaginal contraceptives |
US4602909A (en) | 1982-02-09 | 1986-07-29 | Richter Gedeon Vegyeszeti Gyar Rt | Iontophoresis intermediary material and contact solution for the treatment of chronic pain syndromes |
US4758559A (en) | 1986-01-21 | 1988-07-19 | Ciba-Geigy Corporation | Pyrrolo[1,2-a] [4,1]benzoxazepine derivatives useful as calmodulin and histamine inhibitors |
US4769372A (en) | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4785000A (en) | 1986-06-18 | 1988-11-15 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4788055A (en) | 1985-12-09 | 1988-11-29 | Ciba-Geigy Corporation | Resinate sustained release dextromethorphan composition |
US4806543A (en) | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
US4816264A (en) | 1986-06-06 | 1989-03-28 | Warner-Lambert Company | Sustained release formulations |
US4816450A (en) | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
US4828836A (en) | 1986-06-05 | 1989-05-09 | Euroceltique S.A. | Controlled release pharmaceutical composition |
US4834985A (en) | 1986-06-05 | 1989-05-30 | Euroceltique S.A. | Controlled release pharmaceutical composition |
US4834965A (en) | 1985-07-26 | 1989-05-30 | Euroceltique, S.A. | Controlled release pharmaceutical composition |
US4876276A (en) | 1986-10-24 | 1989-10-24 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | (3S-4S)-7-hydroxy-Δ6 -tetrahydrocannabinols |
US4888347A (en) | 1986-01-14 | 1989-12-19 | Merck Sharp & Dohme Limited | Use of specific N-methyl-D-aspartate receptor antagonists in the prevention and treatment of neurodegeneration |
US4906779A (en) | 1986-07-10 | 1990-03-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
US4912114A (en) | 1988-03-18 | 1990-03-27 | Sandoz Ltd. | Morphinan derivatives |
US4919916A (en) | 1987-08-24 | 1990-04-24 | Golwyn Daniel H | Treatment of neurotransmitter-linked drug abuse |
US4924008A (en) | 1989-05-04 | 1990-05-08 | American Home Products Corporation | Benzobicycloalkane derivatives as anticonvulsant neuroprotective agents |
US4937232A (en) | 1986-09-15 | 1990-06-26 | Duke University | Inhibition of protein kinase C by long-chain bases |
US4942182A (en) | 1989-03-01 | 1990-07-17 | Weiss Susan R B | Treatment for cocaine addiction |
US4959493A (en) | 1987-06-30 | 1990-09-25 | Suntory Limited | Carboxycyclopropylglycine and process for producing the same |
US4975430A (en) | 1989-06-16 | 1990-12-04 | The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University | CNQX and its analogs as therapeutics for degenerative neural diseases |
US4990519A (en) | 1988-10-24 | 1991-02-05 | Merrell Dow Pharmaceuticals | Method of using quinolyloxazole-2-ones as proteinkinase C inhibitors |
US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
US4994446A (en) | 1989-01-03 | 1991-02-19 | Ramot - University Authority For Applied Research And Industrial Development Ltd. | Drug system |
US4996047A (en) | 1988-11-02 | 1991-02-26 | Richardson-Vicks, Inc. | Sustained release drug-resin complexes |
US5006510A (en) | 1989-06-20 | 1991-04-09 | Ellis Wladislaw V | Method for relieving chronic pain with a somatostatin analog composition |
US5013540A (en) | 1989-11-30 | 1991-05-07 | Board Of Regents, The University Of Texas System | Using NMDA receptor antagonists to reduce damage due to laser treatment |
US5023239A (en) | 1986-05-12 | 1991-06-11 | Mect Corporation | Sialosyl cholesterol, process for producing the same, and neuropathy remedy comprising the same |
US5028611A (en) | 1989-06-29 | 1991-07-02 | The Regents Of The University Of Minnesota | Treatment for cocaine use |
US5028707A (en) | 1989-11-20 | 1991-07-02 | Board Of Regents, University Of Texas | 4-hydroxyquinaldic acid derivatives |
US5034395A (en) | 1983-12-02 | 1991-07-23 | Otsuka Pharmaceutical Co., Ltd. | Novel dihydropyridine derivatives |
US5034400A (en) | 1989-10-20 | 1991-07-23 | Olney John W | Method for preventing neurotoxic side effects of NMDA antagonists |
US5041446A (en) | 1988-06-10 | 1991-08-20 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Method for inhibiting the development of tolerance in the analgesic treatment with morphine |
US5047229A (en) | 1986-12-17 | 1991-09-10 | Miles, Inc. | Treatment of cardiovascular and cerebral toxicity using calcium modulators |
US5051442A (en) | 1990-04-25 | 1991-09-24 | Merrell Dow Pharmaceuticals Inc. | 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof |
US5051426A (en) | 1990-03-27 | 1991-09-24 | Parnell Pharmaceuticals, Inc. | Method for effecting withdrawal from drug dependency |
US5055481A (en) | 1989-03-24 | 1991-10-08 | Wakamoto Pharmaceutical Co., Ltd. | Tetrazole derivatives and aldose reductase inhibition therewith |
US5057519A (en) | 1990-06-11 | 1991-10-15 | Bristol-Myers Squibb Company | 5-HT3 antagonists: use in reducing opiate tolerance |
US5068228A (en) | 1987-08-11 | 1991-11-26 | Koehler Gernot | Use of a metal chelate of an alkylaminoester of phosphoric acid for prophytlaxis or therapy of a neuropathy |
US5071646A (en) | 1988-11-11 | 1991-12-10 | Euroceltique, S.A. | Pharmaceutical ion exchange resin composition |
US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
US5091391A (en) | 1990-08-16 | 1992-02-25 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of resisting neurodegenerative disorders |
US5093525A (en) | 1986-07-10 | 1992-03-03 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
US5093129A (en) | 1989-01-30 | 1992-03-03 | E. R. Squibb & Sons, Inc. | Method for treating addiction to a drug of abuse employing an ace inhibitor |
US5095009A (en) | 1990-04-11 | 1992-03-10 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
US5106847A (en) | 1990-07-16 | 1992-04-21 | Merrell Dow Pharmaceuticals Inc. | Excitatory amino acid antagonists, compositions and use |
US5109017A (en) | 1990-09-26 | 1992-04-28 | Fisons Corporation | (2-thienyl)alkylamine derivatives having neuroprotective properties |
US5118675A (en) | 1991-02-15 | 1992-06-02 | American Home Products Corporation | Quinoxaline phosphono-amino acids |
US5124340A (en) | 1989-06-28 | 1992-06-23 | The United States Of America As Represented By The Department Of Health And Human Services | Use of calcium channel blocker to prevent cocaine induced craving and reinforcement |
US5124319A (en) | 1991-10-11 | 1992-06-23 | American Home Products Corporation | Benzimidazole phosphono-amino acids |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5137889A (en) | 1983-12-02 | 1992-08-11 | Otsuka Pharmaceutical Co., Ltd. | Dihydropyridine derivatives and process for preparing the same |
US5137919A (en) | 1990-12-31 | 1992-08-11 | Biomembrane Institute | Effect of N,N,N,-trimethylsphingosine on protein kinase C activity melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation |
US5141957A (en) | 1990-11-02 | 1992-08-25 | Sphinx Pharmaceuticals Corporation | 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c |
US5145842A (en) | 1986-06-11 | 1992-09-08 | Alder Research Center Limited Partnership | Protein kinase c. modulators. d. |
US5151360A (en) | 1990-12-31 | 1992-09-29 | Biomembrane Institute | Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation |
US5166207A (en) | 1991-06-17 | 1992-11-24 | Neurotherapeutics, Inc. | Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders |
US5171752A (en) | 1990-07-19 | 1992-12-15 | Akzo N.V. | Benzhydryl derivatives having calmodulin inhibitor properties |
US5183807A (en) | 1990-06-29 | 1993-02-02 | Fidia S.P.A. | Use of monosialoganglioside gm, to prevent the development of tolerance to the analgesic effect of morphine and related drugs |
US5185329A (en) | 1988-08-30 | 1993-02-09 | Bristol-Myers Squibb Company | Method for treatment of substance addiction |
US5190925A (en) | 1989-06-08 | 1993-03-02 | Fidia, S.P.A. | Use of gangliosides in the treatment of autonomic dysfunction in Chagas' disease |
US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
US5352683A (en) | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
US5441982A (en) | 1993-09-24 | 1995-08-15 | Itzhak; Yossef | Therapeutics for management of cocaine induced toxicity |
-
2001
- 2001-06-15 US US09/880,881 patent/USRE39300E1/en not_active Expired - Lifetime
Patent Citations (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2770569A (en) | 1952-08-01 | 1956-11-13 | Hoffmann La Roche | Analgesic compositions |
US4126684A (en) | 1976-02-11 | 1978-11-21 | Ciba-Geigy Corporation | 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse |
US4416871A (en) | 1978-07-10 | 1983-11-22 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition by peptides of tolerance to and physical dependence on morphine |
US4362870A (en) | 1980-01-16 | 1982-12-07 | Regents Of The University Of Minnesota | Selective opioid receptor alkylating agents |
US4316888A (en) | 1980-04-15 | 1982-02-23 | Nelson Research & Development Co. | Method and composition of reducing pain |
US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
US4446140A (en) | 1981-12-10 | 1984-05-01 | Nelson Research & Development Company | Method and composition for treating mouth pain |
US4602909A (en) | 1982-02-09 | 1986-07-29 | Richter Gedeon Vegyeszeti Gyar Rt | Iontophoresis intermediary material and contact solution for the treatment of chronic pain syndromes |
US4476141A (en) | 1982-07-14 | 1984-10-09 | University Of Georgia Research Foundation, Inc. | Use of N-(6 aminohexyl)-5-chloro-1-naphthalenesulfonamide, N-(6 aminohexyl)-5-chloro-2-naphthalenesulfonamide, and N-(6 aminohexyl)-5-bromo-2-naphthalenesulfonamide as vaginal contraceptives |
US5034395A (en) | 1983-12-02 | 1991-07-23 | Otsuka Pharmaceutical Co., Ltd. | Novel dihydropyridine derivatives |
US5137889A (en) | 1983-12-02 | 1992-08-11 | Otsuka Pharmaceutical Co., Ltd. | Dihydropyridine derivatives and process for preparing the same |
US4834965A (en) | 1985-07-26 | 1989-05-30 | Euroceltique, S.A. | Controlled release pharmaceutical composition |
US4788055A (en) | 1985-12-09 | 1988-11-29 | Ciba-Geigy Corporation | Resinate sustained release dextromethorphan composition |
US4888347A (en) | 1986-01-14 | 1989-12-19 | Merck Sharp & Dohme Limited | Use of specific N-methyl-D-aspartate receptor antagonists in the prevention and treatment of neurodegeneration |
US4758559A (en) | 1986-01-21 | 1988-07-19 | Ciba-Geigy Corporation | Pyrrolo[1,2-a] [4,1]benzoxazepine derivatives useful as calmodulin and histamine inhibitors |
US5126330A (en) | 1986-05-12 | 1992-06-30 | Mect Corporation | Sialosyl cholesterol and neuropathy remedy comprising the same |
US5023239A (en) | 1986-05-12 | 1991-06-11 | Mect Corporation | Sialosyl cholesterol, process for producing the same, and neuropathy remedy comprising the same |
US4828836A (en) | 1986-06-05 | 1989-05-09 | Euroceltique S.A. | Controlled release pharmaceutical composition |
US4834985A (en) | 1986-06-05 | 1989-05-30 | Euroceltique S.A. | Controlled release pharmaceutical composition |
US4816264A (en) | 1986-06-06 | 1989-03-28 | Warner-Lambert Company | Sustained release formulations |
US5145842A (en) | 1986-06-11 | 1992-09-08 | Alder Research Center Limited Partnership | Protein kinase c. modulators. d. |
US4785000A (en) | 1986-06-18 | 1988-11-15 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4769372A (en) | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4906779A (en) | 1986-07-10 | 1990-03-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
US5093525A (en) | 1986-07-10 | 1992-03-03 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
US4937232A (en) | 1986-09-15 | 1990-06-26 | Duke University | Inhibition of protein kinase C by long-chain bases |
US4816450A (en) | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
US4876276A (en) | 1986-10-24 | 1989-10-24 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | (3S-4S)-7-hydroxy-Δ6 -tetrahydrocannabinols |
US4806543A (en) | 1986-11-25 | 1989-02-21 | Board Of Trustees Of The Leland Stanford Junior University | Method and compositions for reducing neurotoxic injury |
US5047229A (en) | 1986-12-17 | 1991-09-10 | Miles, Inc. | Treatment of cardiovascular and cerebral toxicity using calcium modulators |
US4959493A (en) | 1987-06-30 | 1990-09-25 | Suntory Limited | Carboxycyclopropylglycine and process for producing the same |
US5068228A (en) | 1987-08-11 | 1991-11-26 | Koehler Gernot | Use of a metal chelate of an alkylaminoester of phosphoric acid for prophytlaxis or therapy of a neuropathy |
US4919916A (en) | 1987-08-24 | 1990-04-24 | Golwyn Daniel H | Treatment of neurotransmitter-linked drug abuse |
US4912114A (en) | 1988-03-18 | 1990-03-27 | Sandoz Ltd. | Morphinan derivatives |
US5041446A (en) | 1988-06-10 | 1991-08-20 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Method for inhibiting the development of tolerance in the analgesic treatment with morphine |
US5185329A (en) | 1988-08-30 | 1993-02-09 | Bristol-Myers Squibb Company | Method for treatment of substance addiction |
US4990519A (en) | 1988-10-24 | 1991-02-05 | Merrell Dow Pharmaceuticals | Method of using quinolyloxazole-2-ones as proteinkinase C inhibitors |
US4996047A (en) | 1988-11-02 | 1991-02-26 | Richardson-Vicks, Inc. | Sustained release drug-resin complexes |
US5071646A (en) | 1988-11-11 | 1991-12-10 | Euroceltique, S.A. | Pharmaceutical ion exchange resin composition |
US4994446A (en) | 1989-01-03 | 1991-02-19 | Ramot - University Authority For Applied Research And Industrial Development Ltd. | Drug system |
US5093129A (en) | 1989-01-30 | 1992-03-03 | E. R. Squibb & Sons, Inc. | Method for treating addiction to a drug of abuse employing an ace inhibitor |
US4942182A (en) | 1989-03-01 | 1990-07-17 | Weiss Susan R B | Treatment for cocaine addiction |
US5055481A (en) | 1989-03-24 | 1991-10-08 | Wakamoto Pharmaceutical Co., Ltd. | Tetrazole derivatives and aldose reductase inhibition therewith |
US4924008A (en) | 1989-05-04 | 1990-05-08 | American Home Products Corporation | Benzobicycloalkane derivatives as anticonvulsant neuroprotective agents |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
US5190925A (en) | 1989-06-08 | 1993-03-02 | Fidia, S.P.A. | Use of gangliosides in the treatment of autonomic dysfunction in Chagas' disease |
US4975430A (en) | 1989-06-16 | 1990-12-04 | The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University | CNQX and its analogs as therapeutics for degenerative neural diseases |
US5006510A (en) | 1989-06-20 | 1991-04-09 | Ellis Wladislaw V | Method for relieving chronic pain with a somatostatin analog composition |
US5124340A (en) | 1989-06-28 | 1992-06-23 | The United States Of America As Represented By The Department Of Health And Human Services | Use of calcium channel blocker to prevent cocaine induced craving and reinforcement |
US5028611A (en) | 1989-06-29 | 1991-07-02 | The Regents Of The University Of Minnesota | Treatment for cocaine use |
US5034400A (en) | 1989-10-20 | 1991-07-23 | Olney John W | Method for preventing neurotoxic side effects of NMDA antagonists |
US5028707A (en) | 1989-11-20 | 1991-07-02 | Board Of Regents, University Of Texas | 4-hydroxyquinaldic acid derivatives |
US5013540A (en) | 1989-11-30 | 1991-05-07 | Board Of Regents, The University Of Texas System | Using NMDA receptor antagonists to reduce damage due to laser treatment |
US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
US5051426A (en) | 1990-03-27 | 1991-09-24 | Parnell Pharmaceuticals, Inc. | Method for effecting withdrawal from drug dependency |
US5095009A (en) | 1990-04-11 | 1992-03-10 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
US5051442A (en) | 1990-04-25 | 1991-09-24 | Merrell Dow Pharmaceuticals Inc. | 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof |
US5057519A (en) | 1990-06-11 | 1991-10-15 | Bristol-Myers Squibb Company | 5-HT3 antagonists: use in reducing opiate tolerance |
US5183807A (en) | 1990-06-29 | 1993-02-02 | Fidia S.P.A. | Use of monosialoganglioside gm, to prevent the development of tolerance to the analgesic effect of morphine and related drugs |
US5106847A (en) | 1990-07-16 | 1992-04-21 | Merrell Dow Pharmaceuticals Inc. | Excitatory amino acid antagonists, compositions and use |
US5171752A (en) | 1990-07-19 | 1992-12-15 | Akzo N.V. | Benzhydryl derivatives having calmodulin inhibitor properties |
US5091391A (en) | 1990-08-16 | 1992-02-25 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of resisting neurodegenerative disorders |
US5109017A (en) | 1990-09-26 | 1992-04-28 | Fisons Corporation | (2-thienyl)alkylamine derivatives having neuroprotective properties |
US5141957A (en) | 1990-11-02 | 1992-08-25 | Sphinx Pharmaceuticals Corporation | 1,4-bis-(amino-hydroxyalkylamino)-anthraquinones for inhibiting protein kinase c |
US5137919A (en) | 1990-12-31 | 1992-08-11 | Biomembrane Institute | Effect of N,N,N,-trimethylsphingosine on protein kinase C activity melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation |
US5151360A (en) | 1990-12-31 | 1992-09-29 | Biomembrane Institute | Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation |
US5118675A (en) | 1991-02-15 | 1992-06-02 | American Home Products Corporation | Quinoxaline phosphono-amino acids |
US5166207A (en) | 1991-06-17 | 1992-11-24 | Neurotherapeutics, Inc. | Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders |
US5124319A (en) | 1991-10-11 | 1992-06-23 | American Home Products Corporation | Benzimidazole phosphono-amino acids |
US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
US5654281A (en) | 1993-01-28 | 1997-08-05 | Virginia Commonwealth University | Inhibiting the development of tolerance to and/or dependence on an addictive substance |
US5352683A (en) | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
US5441982A (en) | 1993-09-24 | 1995-08-15 | Itzhak; Yossef | Therapeutics for management of cocaine induced toxicity |
Non-Patent Citations (32)
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060111308A1 (en) * | 2004-11-16 | 2006-05-25 | Wendye Robbins | Methods and compositions for therapeutic treatment |
US20060111307A1 (en) * | 2004-11-16 | 2006-05-25 | Wendye Robbins | Methods and compositions for treating pain |
US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
US20090088394A1 (en) * | 2004-11-16 | 2009-04-02 | Wendye Robbins | Methods and compositions for therapeutic treatment |
US20080241121A1 (en) * | 2007-04-02 | 2008-10-02 | Daniela Salvemini | Inhibitors of the ceramide metabolic pathway as adjuncts to opiates for pain |
US20100086543A1 (en) * | 2007-04-02 | 2010-04-08 | Saint Louis University | Compositions and methods for treating conditions associated with ceramide biosynthesis |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5556838A (en) | Inhibiting the development of tolerance to and/or dependence on an addictive substance | |
CA1069050A (en) | Pharmaceutical compositions for combating the misuse of addicting agents | |
US5919826A (en) | Method of alleviating pain | |
EP1414459B1 (en) | Oral dosage form comprising a therapeutic agent and an adverse-effect agent | |
EP0845989B1 (en) | Pain-alleviating drug composition | |
EP1003494B1 (en) | (d)-METHADONE, A NONOPIOID ANALGESIC | |
WO2004050020A2 (en) | Improved opioid pharmaceutical compositions | |
US20220023310A1 (en) | Methods for acute and long-term treatment of opioid and opioid-like drug addiction | |
US20150231146A1 (en) | Methods for acute and long-term treatment of drug addiction | |
EP0031234A1 (en) | Analgesic composition | |
USRE39300E1 (en) | Inhibiting the development of tolerance to and/or dependence on an addictive substance | |
EP0778770B1 (en) | Composition alleviating pain, containing a non-narcotic analgesic and an analgesia enhancer | |
US20170157055A1 (en) | Pharmaceutical abuse deterrent composition | |
Kuperman et al. | Myoelectric activity of the small intestine during morphine dependence and withdrawal in rats | |
US20210046014A1 (en) | Pharmaceutical abuse deterrent composition constructed in more than one strengths | |
WO2019064082A2 (en) | Pharmaceutical abuse deterrent composition constructed in more than one strengths | |
AU2011205217B2 (en) | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Fee payment |
Year of fee payment: 12 |